Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Claims for obesity were noted in 31% (n = 426) of patients in the combined population, vitamin D deficiency in 26% (n = 349), renal disease in 21% (n = 280), hypertension in 18% (n = 249), depression in 18% (n = 247), and fracture in 17% (n = 232), with 15% (n = 197) having claims associated with codes for hearing loss (Fig. 2).

Source: Morbidities and other complications. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This retrospective cohort study used Komodo Health’s Healthcare Map™, a de-identified patient-level claims database.

Source: Abstract.

In each dataset patients were included if they had ≥ 1 claim for familial hypophosphatemia or other disorders of phosphate metabolism within the study period (International Classification of Diseases, 10th Edition, Clinical Modification [ICD-10-CM] E83.31, E83.39, ICD-9-CM 2753) and ≥ 1 claim for burosumab between 01-Apr-2018 and 30-Jun-2022.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab

Cohort study · Archives of Osteoporosis · 2025

Original publication title

Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab

Kathryn M. Dahir; Zhiyi Li; Heather M. Heerssen; Ahmed Noman; Jeremy Kim; Yang Zhao; Erik A. Imel

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

At initiation of burosumab, over half of patients with XLH were < 18 years of age. Claims indicated a high prevalence of XLH-related morbidities, which began at a young age and increased over time.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To examine the characteristics and disease history of real-world patients with X-linked hypophosphatemia (XLH) in the United States, prior to initiating burosumab.

Source: Purpose

Abstract: What methods does the paper describe?

This retrospective cohort study used Komodo Health’s Healthcare Map™, a de-identified patient-level claims database. Included patients had ≥ 1 claim for familial hypophosphatemia between 01-Jan-2015 and 30-Jun-2022 (the study period) and ≥ 1 claim for burosumab between 01-Apr-2018 and 30-Jun-2022. The index date was the date of first burosumab claim. Patient demographics were measured at index; disease history was measured over the pre-index period and stratified by age. All variables were evaluated descriptively.

Source: Methods

Abstract: Summary

In a United States claims database, 1,358 persons with familial hypophosphatemia who began treatment with burosumab were identified. Prior to treatment, high rates of several morbidities were coded including osteoarthritis, fractures, enthesopathy, spinal stenosis, hypertension, depression and opioid use, which generally increased with age, emphasizing disease burden throughout the lifespan.

Source: Summary

Abstract: Results

1,358 patients were included (mean age 23.5 ± 19.1 years, 847 [62%] female); 720 patients (53%) were aged < 18 years. Prior to index, patients had high levels of XLH-related morbidities. Most XLH-related morbidities appeared in the youngest age groups, and the prevalence was generally greater among the older age groups. For example, arthralgia was found in 57 patients (12%) aged ≤ 11 years and 123 patients (69%) aged ≥ 50 years. Opioid use increased with age (173 patients [24%] aged < 18 years; 328 [51%] ≥ 18 years).

Physical therapy use was observed across age groups (126 patients [18%] aged < 18 years; 253 [40%] ≥ 18 years).

Source: Results

Abstract: Conclusions

At initiation of burosumab, over half of patients with XLH were < 18 years of age. Claims indicated a high prevalence of XLH-related morbidities, which began at a young age and increased over time.

Source: Conclusions
Authors’ abstract

Summary

In a United States claims database, 1,358 persons with familial hypophosphatemia who began treatment with burosumab were identified. Prior to treatment, high rates of several morbidities were coded including osteoarthritis, fractures, enthesopathy, spinal stenosis, hypertension, depression and opioid use, which generally increased with age, emphasizing disease burden throughout the lifespan.

Purpose

To examine the characteristics and disease history of real-world patients with X-linked hypophosphatemia (XLH) in the United States, prior to initiating burosumab.

Methods

This retrospective cohort study used Komodo Health’s Healthcare Map™, a de-identified patient-level claims database. Included patients had ≥ 1 claim for familial hypophosphatemia between 01-Jan-2015 and 30-Jun-2022 (the study period) and ≥ 1 claim for burosumab between 01-Apr-2018 and 30-Jun-2022. The index date was the date of first burosumab claim. Patient demographics were measured at index; disease history was measured over the pre-index period and stratified by age. All variables were evaluated descriptively.

Results

1,358 patients were included (mean age 23.5 ± 19.1 years, 847 [62%] female); 720 patients (53%) were aged < 18 years. Prior to index, patients had high levels of XLH-related morbidities. Most XLH-related morbidities appeared in the youngest age groups, and the prevalence was generally greater among the older age groups. For example, arthralgia was found in 57 patients (12%) aged ≤ 11 years and 123 patients (69%) aged ≥ 50 years. Opioid use increased with age (173 patients [24%] aged < 18 years; 328 [51%] ≥ 18 years).

Physical therapy use was observed across age groups (126 patients [18%] aged < 18 years; 253 [40%] ≥ 18 years).

Conclusions

At initiation of burosumab, over half of patients with XLH were < 18 years of age. Claims indicated a high prevalence of XLH-related morbidities, which began at a young age and increased over time.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11657-025-01544-1.

Publication and source details

Original title: Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab

Kathryn M. Dahir; Zhiyi Li; Heather M. Heerssen; Ahmed Noman; Jeremy Kim; Yang Zhao; Erik A. Imel

Archives of Osteoporosis · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/100016348Kyowa Kirin Pharmaceutical Development

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:12:27.666397+00:00

DOI: 10.1007/s11657-025-01544-1 · PMC12075324